H. Lundbeck, Phase II clinical results announced for gaboxadol

Acute administration of gaboxadol significantly improved several key sleep measures in patients with primary insomnia
H. Lundbeck A/S and Merck & Co., Inc. announced today, at the 19th Annual Meeting of the Associated Professional Sleep Societies (APSS), results of a Phase II clinical trial with gaboxadol, an investigational agent in Phase III for the treatment of insomnia and the first Selective Extrasynaptic GABAA Agonist (SEGA), a new class of sleep agents.